trending Market Intelligence /marketintelligence/en/news-insights/trending/ms0rmatbdzauvu8vgyapza2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Altimmune starts $25M registered direct offering to fund product development

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Altimmune starts $25M registered direct offering to fund product development

Altimmune Inc. agreed to sell 4,629,630 units, including common and pre-funded units, to institutional investors in a registered direct offering to raise about $25 million in gross proceeds.

Each common unit is priced at $5.40 and includes 1 common share and 1 warrant to purchase a common share for $5.40. The warrant is exercisable from the date of issuance up to five years.

The pre-funded units are priced at $5.39 apiece and include a warrant to purchase 1 common share at an exercise price of 1 cent and another warrant to purchase 1 common share at an exercise price of $5.40. Pre-funded warrants are exercisable until all of the pre-funded warrants are exercised in full.

Gaithersburg, Md.-based Altimmune intends to use the proceeds to fund development of its experimental immunotherapies and vaccines against infectious diseases, general corporate purposes and strategic growth opportunities.

The offering is expected to close Oct. 10.

Roth Capital Partners is the sole placement agent for the offering.